Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | 12 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 11 Parkinson's papers of 1,844 | 0.67 |
| pathways Reactome | 10 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 4068
Sealed predictions
- ATF2 in dopamine neurons, braak+0.37 (p 0.334) → +0.28 (p 0.459)receipt 4076
Swarm cases
receipt 4076: ATF2 in dopamine neurons, braak
- power
- full sample +0.35 (p 0.150, n 18), 95% CI -0.14 to +0.70. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.40 (p 0.103, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.46 (p 0.055, n 18). could be the mix.
- skeptic
- leave-one-out range +0.28 to +0.49, sign flips 0; without severely affected donors +0.35 (p 0.150, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.72 (p 7.0e-4, n 18) vs +0.35 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ATF2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ATF2 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.90 p 0.0014 (needs p < 4.8e-4)
Receipts
loading the receipts